TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Physical Activity Domain Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Trough Concentration of Sirolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in attitudes, beliefs, and intentions about alcohol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Cure/Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Immune Response to T Cell Stimulation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tolerance to KLH Using T Cell Stimulation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in peritoneal small solute transport (Kt/V)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peritoneal ultrafiltration rate on PET test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of COVID-19 cases
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of SAE
Endpoint domain: Adverse events/effects
Primary endpoint: Change in laser Doppler parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Occurrence of CRS (Cytokine Release Syndrome)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in HDL Immunomodulatory Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in dietary patterns
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Perception of lifestyle
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: One-time Screening Completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Episodic memory retrieval performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of Cholestasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of participants with R0 resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reaction Time to Facial Affect Identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amygdala BOLD Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Two-weeks survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Apparent Volume of Distribution of Radioactivity in Whole Blood (V/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration in Plasma Radioactivity (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ART Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acne IGA rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instrumental Activities of Daily Living (MDS-HC-IADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CABPad Working Memory Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: FACT-An
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Numeric Rating Scale on symptoms of anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Who Did Not Experience a Dose Limiting Toxicity in the Less Than 3 Centimeter Cohort
Endpoint domain: Adverse events/effects
Primary endpoint: Participants Who Did Not Experience a Dose Limiting Toxicity in the More Than 3 Centimeter Cohort
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Sputum Neutrophil Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of Clinical Effect of LIPO-202
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Photonumeric Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Abdominal Perception Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fever (oral temperature ≥101°F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scores Bath Ankylosing Spondylitis Disease Activity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scores Bath Ankylosing Spondylitis Functional Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scores Ankylosing Spondylitis Quality of Life Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain Score at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug Liking Visual Analog Scale (VAS) Emax Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: arterial blood oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hydromorphone consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Urinary Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients who develop hypercalcuria
Endpoint domain: Adverse events/effects
Primary endpoint: Sinus
Endpoint domain: Adverse events/effects
Primary endpoint: Tooth mobility
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with ACR20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Achieving Trough hGH Concentration <2.5µg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number and severity of adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Minimum inhibitory concentration (MIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of Adverse Events (AEs) of Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Propofol plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simultaneous exhaled concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain score change after 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal interleukine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: donor recovery/quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Puncture-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Composite safety score
Endpoint domain: Adverse events/effects
Primary endpoint: Bleeding Patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Marked Polyp Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Median Number of Treatment-Related Adverse Events Per Participant
Endpoint domain: Adverse events/effects
Primary endpoint: BMI change at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BMI change at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: annual rate of change in CD4 count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of sensory infraclavicular block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated radiation dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dialysis appointment attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CSF pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 1-year relapse-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Relief of OSAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative delirium score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FAP and autophagy markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax - maximum observed plasma concentration (single dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ - area under the plasma concentration versus time curve (single dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ - area under the plasma concentration versus time curve from time zero to infinity (single dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in muscle derived protein synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bio-distribution and radiation dosimetry of [F-18]T807
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolism of [F-18]T807
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: [F-18]T807 uptake and signal/background information
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of IV administration of [F-18]T807
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with abnormal pharmacokinetics of isoniazid and rifabutin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete resolution of heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in albuminuria based on urinary albumin-creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ALS Functional rating Scale-revised (ALS FRS-R) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of time non-cooperative
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Erythema and desquamation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: total dose of intravenous morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Oxygen Concentration at the Lips
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen Concentration at the Oropharyngeal Location
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in periodontal disease parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in YMRS and Hamilton - D scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative score reported in GAF scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in blood volume during blood draw
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in cognitive status
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of delirium until day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell biodistribution after intravenous infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Live Births
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of ileal digestibility of pea proteins and casein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of ileal digestibility of amino acids from pea proteins and casein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of net postprandial protein utilization of pea proteins and casein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hepatitis B virus (HBV) vaccine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Sampled for RNA-seq Differential Expression Analysis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of HD-tDCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clean Urine Drug Screen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in salivary alpha-amylase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Diurnal Intraocular Pressure (DIOP) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rejection Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical evaluation of pulpotomies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic evaluation of pulpotomies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathologic evaluation of pulpotomies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration curve from time 0 to the last measured (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in inflammatory and anti-inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: postoperative analgesic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events following treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Stromal tissue consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence/persistence of activity-limiting knee pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-reported Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Disability / Limitations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Standard of care antibiotic prophylaxis effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Stem subsidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lactic acid measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Procalcitonin (PCT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Food intake (grams and kcal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in the Total International Prostate Symptom Score (IPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time incision to skin closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in severity of pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTD dose of NC-6300
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RPII dose of NC-6300
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for stratum corneum lipid composition to become indistinguishable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tongue area on ultrasonography imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of the intensity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined clinical and mycological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification and characterization of new CD8+ T lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of CUP patients receiving matched targeted therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Aflibercept Injections Successfully Administered
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Self-report on Katz Activity of Daily Living (ADL) Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Life Space Assessment
Endpoint domain: Life impact
Endpoint subdomain: Mobility
Primary endpoint: Change of Tumor Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hepatic vein pressure gradient (HVPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance in detecting bone metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of the PET tracer in the lung and associated neoplasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Wolf Motor Function Test - Functional Ability Scale (WMFT-FAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number RPE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative analysis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Montreal Cognitive Assessment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fasting HDL concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Doppler Flow Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Main Reason for the Use of Sirolimus Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum tolerated dose (MTD) of pazopanib and GSK1120212
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events as a measure of safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Radiological atelectasis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outcome of children with SE at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days spent in the hospital due to VAD-associated complications
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Score on Faces Pain Scale - Revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fasting serum TG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Grade of macroscopic contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adhesive Residue Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Application Site Dermal-Erythema, Edema, and Irritation Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pharmacokinetic endpoints (plasma varenicline AUClast, AUCinf, Cmax, t 1/2, Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance to RAD001
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in balance and gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries increment in primary teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Change From Baseline in OAS-M Total Aggression Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Are Able to Achieve Control of Disease Activity (CDA) Within 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 20 km cycling time trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Positive Sensitive Blood Smear (sBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Local and Systemic Grade 3 Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Local and Systemic Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: abnormalities in brain structure and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum tolerated dose (MTD) / Maximum feasible dose (MFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint position sense error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who would recommend the C-Care App
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status